November 2016November 2016
New Product - Decapeptyl
Decapeptyl (triptorelin acetate) a gonadotropin releasing hormone (GnRH) agonist, inhibits gonadotropin secretion when given continuously and in therapeutic doses. After the administration of triptorelin there is an initial and transient increase in circulating follicle-stimulating hormone (FSH) and luteinising hormone (LH) levels (flare-up). Continued administration of triptorelin then results in decreased FSH and LH secretion with a consequent marked reduction in gonadal hormone production. Decapeptyl is indicated for down regulation and prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART). In clinical trials Decapeptyl 100 micrograms/1 mL has been used in cycles where urinary and recombinant human follicle stimulating hormone (FSH) as well as human menopausal gonadotrophin (HMG) were used for stimulation. Decapeptyl is contraindicated in cases of: hypersensitivity to gonadotropin releasing hormone (GnRH) or any other GnRH analogue; pregnancy and lactation. Women of childbearing potential should be examined carefully before treatment to exclude pregnancy. Decapeptyl is available as a 100 micrograms/1 mL prefilled syringe for subcutaneous injection in vials of 7’s.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au